BioSim™ Pembrolizumab(Keytruda®)(Human) ELISA Kit

Alternate Name :

Tag Line :

A Sandwich ELISA kit for the quantitative measurement of Pembrolizumab in human serum or plasma.

Storage Conditions: 4°C

Shelf life: 12 months

Summary :

• Detection method- Absorbance (450 nm)
• Species reactivity- Human
• Application- quantitative measurement of Pembrolizumab in human serum and plasma

Detection Method: Absorbance (450 nm)

Features & Benefits:

• Easy, convenient, sensitive and time-saving method to measure the level of Pembrolizumab in human serum and plasma.
• Detection Range: 30 - 1000 ng/ml
• Sensitivity: 10 ng/ml
• Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
• Recovery rate: 85 – 115% with normal human serum samples with known concentrations
• Cross Reactivity: There is no cross reaction with native serum immunoglobulins and tested monoclonal antibodies such as infliximab (Remicade®), adalimumab (Humira®) , etanercept (Enbrel®), bevacizumab (Avastin®) and trastuzumab (Herceptin®)

Description:

Pembrolizumab (Keytruda®) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells. BioSim™ Pembrolizumab ELISA kit has been developed for specific quantification of Pembrolizumab concentration in human serum or plasma with high sensitivity and reproducibility.